Insider Selling: GeneDx Holdings Corp. (NASDAQ:WGS) CFO Sells 12,019 Shares of Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 12,019 shares of the business’s stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $73.76, for a total value of $886,521.44. Following the transaction, the chief financial officer now directly owns 32,932 shares in the company, valued at $2,429,064.32. This trade represents a 26.74 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Kevin Feeley also recently made the following trade(s):

• On Tuesday, October 29th, Kevin Feeley sold 274 shares of GeneDx stock. The stock was sold at an average price of $66.60, for a total transaction of $18,248.40.
• On Monday, September 9th, Kevin Feeley sold 895 shares of GeneDx stock. The shares were sold at an average price of $33.33, for a total transaction of $29,830.35.
• On Tuesday, September 3rd, Kevin Feeley sold 262 shares of GeneDx stock. The shares were sold at an average price of $31.71, for a total value of $8,308.02.

GeneDx Trading Down 1.4 %

NASDAQ:WGS opened at $79.43 on Thursday. GeneDx Holdings Corp. has a 12-month low of $1.45 and a 12-month high of $89.11. The firm has a market cap of $2.18 billion, a PE ratio of -25.58 and a beta of 2.11. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. The stock has a fifty day moving average price of $61.33 and a 200 day moving average price of $40.68.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.25. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. The company had revenue of $76.90 million during the quarter, compared to the consensus estimate of $64.98 million. During the same quarter in the previous year, the firm earned ($0.82) earnings per share. The firm’s quarterly revenue was up 44.3% on a year-over-year basis. Sell-side analysts anticipate that GeneDx Holdings Corp. will post -0.24 earnings per share for the current fiscal year.

Institutional Trading of GeneDx

A number of institutional investors have recently bought and sold shares of WGS. Renaissance Technologies LLC acquired a new position in GeneDx in the second quarter valued at approximately $2,362,000. Lisanti Capital Growth LLC purchased a new position in shares of GeneDx in the 3rd quarter valued at $1,554,000. Chartwell Investment Partners LLC acquired a new stake in GeneDx during the 3rd quarter worth $1,722,000. Millennium Management LLC lifted its position in GeneDx by 193.5% in the second quarter. Millennium Management LLC now owns 311,401 shares of the company’s stock valued at $8,140,000 after acquiring an additional 205,318 shares during the last quarter. Finally, Algert Global LLC purchased a new position in shares of GeneDx during the second quarter worth about $356,000. 61.72% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

WGS has been the topic of several recent analyst reports. BTIG Research upped their price target on GeneDx from $35.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, July 31st. Craig Hallum boosted their price target on shares of GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. The Goldman Sachs Group lifted their target price on shares of GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Wells Fargo & Company raised their price target on GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 30th. Finally, TD Cowen boosted their price objective on GeneDx from $46.00 to $50.00 and gave the company a “buy” rating in a report on Wednesday, July 31st. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $59.33.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.